STOCK TITAN

Camac Fund takes 5.3% activist stake in Cryo-Cell (CCEL) with 430,900 shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Camac Fund and related entities disclosed a 5.3% stake in Cryo-Cell International, Inc. common stock on a Schedule 13D. They report beneficial ownership of 430,900 shares, acquired for approximately $1,354,672, based on 8,055,150 shares outstanding as stated in Cryo-Cell’s Form 10-K for the period ended November 30, 2026.

The position was purchased with working capital and is held through Camac Fund, with Camac Partners, Camac Capital and Eric Shahinian sharing voting and dispositive power. The investors state they believed the shares were undervalued and may increase or decrease their holdings or use hedging strategies over time.

The group describes itself as active, indicating plans to periodically review the investment and potentially engage with Cryo-Cell’s management, Board, other stockholders and third parties on topics such as Board composition and corporate governance, spending levels, monetization of company assets and return of capital to shareholders.

Positive

  • None.

Negative

  • None.

Insights

13D shows a new 5.3% activist-style holder in Cryo-Cell.

Camac Fund and affiliated entities report owning 430,900 Cryo-Cell shares, or 5.3% of the common stock, bought for about $1,354,672. Crossing 5% and filing a Schedule 13D instead of 13G signals an active investment approach rather than a purely passive stake.

The filing states the group saw the stock as undervalued and may trade around the position or hedge exposure. More importantly, they may engage with management and the Board on governance, spending, asset monetization and returning capital. Any concrete proposals would appear in future company or investor communications.

The impact will depend on whether Camac pushes for Board changes, strategic reviews or capital actions, and how other shareholders respond. For now, this establishes an organized shareholder with meaningful influence but no specific restructuring or transaction plan disclosed in the excerpt.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Camac Partners, LLC
Signature:/s/ Eric Shahinian
Name/Title:Eric Shahinian/Managing Member of the GP
Date:03/25/2026
Camac Capital, LLC
Signature:/s/ Eric Shahinian
Name/Title:Eric Shahinian/Managing Member
Date:03/25/2026
Signature:/s/ Eric Shahinian
Name/Title:Eric Shahinian
Date:03/25/2026
Camac Fund, LP
Signature:/s/ Eric Shahinian/general partner
Name/Title:Eric Shahinian/Managing Member of the GP
Date:03/25/2026
Eric Shahinian
Signature:/s/ Eric Shahinian
Name/Title:Eric Shahinian
Date:03/25/2026

FAQ

What stake did Camac Fund disclose in Cryo-Cell International (CCEL)?

Camac Fund and related entities disclosed beneficial ownership of 430,900 shares of Cryo-Cell common stock, representing approximately 5.3% of the outstanding shares, based on 8,055,150 shares reported in the company’s Form 10-K for the period ended November 30, 2026.

How much did Camac Fund pay for its Cryo-Cell (CCEL) position?

Camac Fund reports an aggregate purchase price of approximately $1,354,672 for the 430,900 Cryo-Cell shares it beneficially owns. The filing states these purchases were funded with working capital, which may at times include margin loans from brokerage firms in the ordinary course of business.

Why did Camac Fund file a Schedule 13D on Cryo-Cell (CCEL)?

The investors chose a Schedule 13D because they view Cryo-Cell shares as undervalued and are not committing to a passive stance. They indicate they may change their position size, use hedging strategies, and engage with management and the Board on governance, spending, asset monetization and capital return.

Who are the reporting persons in the Cryo-Cell (CCEL) Schedule 13D?

The reporting persons are Camac Partners, LLC, Camac Capital, LLC, Camac Fund, LP and individual investor Eric Shahinian. Camac Partners manages Camac Fund, Camac Capital is its general partner, and Shahinian manages Camac Capital, giving them shared voting and dispositive power over the reported shares.

What governance or strategic topics might Camac raise at Cryo-Cell (CCEL)?

The filing notes the group may discuss Board composition and corporate governance, company expenditure levels, monetization of all the company’s assets and potential return of capital to shareholders. They intend to review their investment periodically and may adjust their plans over time based on these reviews.
Cryo-Cell Intl Inc

NYSE:CCEL

View CCEL Stock Overview

CCEL Rankings

CCEL Latest News

CCEL Latest SEC Filings

CCEL Stock Data

23.92M
4.26M
Medical Care Facilities
Services-misc Health & Allied Services, Nec
Link
United States
OLDSMAR